Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Novel investigational therapeutics for generalized anxiety disorder (GAD).

Schanzer B, Rivas-Grajales AM, Khan A, Mathew SJ.

Expert Opin Investig Drugs. 2019 Nov;28(11):1003-1012. doi: 10.1080/13543784.2019.1680638. Epub 2019 Oct 28. Review.

PMID:
31607187
2.

The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression.

O'Brien B, Lijffijt M, Wells A, Swann AC, Mathew SJ.

Pharmaceuticals (Basel). 2019 Sep 11;12(3). pii: E133. doi: 10.3390/ph12030133.

3.

Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.

Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI.

J Affect Disord. 2020 Jan 1;260:131-139. doi: 10.1016/j.jad.2019.09.017. Epub 2019 Sep 3.

PMID:
31494365
4.

Longer-term open-label study of adjunctive riluzole in treatment-resistant depression.

Sakurai H, Dording C, Yeung A, Foster S, Jain F, Chang T, Trinh NH, Bernard R, Boyden S, Iqbal SZ, Wilkinson ST, Mathew SJ, Mischoulon D, Fava M, Cusin C.

J Affect Disord. 2019 Nov 1;258:102-108. doi: 10.1016/j.jad.2019.06.065. Epub 2019 Jul 2.

PMID:
31400624
5.

"Does the opioid system block or enhance the antidepressant effects of ketamine?"

Mathew SJ, Rivas-Grajales AM.

Chronic Stress (Thousand Oaks). 2019 Jan-Dec/;3. doi: 10.1177/2470547019852073. Epub 2019 Jun 16. No abstract available.

6.

A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial.

Dakwar E, Nunes EV, Hart CL, Foltin RW, Mathew SJ, Carpenter KM, Choi CJJ, Basaraba CN, Pavlicova M, Levin FR.

Am J Psychiatry. 2019 Nov 1;176(11):923-930. doi: 10.1176/appi.ajp.2019.18101123. Epub 2019 Jun 24.

PMID:
31230464
7.

Interactions of immediate and long-term action regulation in the course and complications of bipolar disorder.

Lijffijt M, O'Brien B, Salas R, Mathew SJ, Swann AC.

Philos Trans R Soc Lond B Biol Sci. 2019 Feb 18;374(1766):20180132. doi: 10.1098/rstb.2018.0132.

PMID:
30966917
8.

Trajectories of self-reported sleep disturbance across inpatient psychiatric treatment predict clinical outcome in comorbid major depressive disorder and generalized anxiety disorder.

Hartwig EM, Rufino KA, Palmer CA, Shepard C, Alfano CA, Schanzer B, Mathew SJ, Patriquin MA.

J Affect Disord. 2019 May 15;251:248-255. doi: 10.1016/j.jad.2019.03.069. Epub 2019 Mar 22.

PMID:
30953891
9.

Myosin heavy chain mutations that cause Freeman-Sheldon syndrome lead to muscle structural and functional defects in Drosophila.

Das S, Kumar P, Verma A, Maiti TK, Mathew SJ.

Dev Biol. 2019 May 15;449(2):90-98. doi: 10.1016/j.ydbio.2019.02.017. Epub 2019 Feb 28.

10.

Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients.

Jovanovic T, Duncan EJ, Kaye J, Garza K, Norrholm SD, Inslicht SS, Neylan TC, Mathew SJ, Iosifescu D, Rothbaum BO, Mayberg HS, Dunlop BW.

Psychophysiology. 2019 Feb 26:e13356. doi: 10.1111/psyp.13356. [Epub ahead of print]

PMID:
30807663
11.

Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.

Wilkinson ST, Farmer C, Ballard ED, Mathew SJ, Grunebaum MF, Murrough JW, Sos P, Wang G, Gueorguieva R, Zarate CA Jr.

Neuropsychopharmacology. 2019 Jun;44(7):1233-1238. doi: 10.1038/s41386-019-0317-8. Epub 2019 Jan 17.

PMID:
30653192
12.

Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI.

Mol Psychiatry. 2019 Jan 7. doi: 10.1038/s41380-018-0311-2. [Epub ahead of print]

PMID:
30617276
13.

Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.

Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI.

Depress Anxiety. 2019 Mar;36(3):235-243. doi: 10.1002/da.22875. Epub 2018 Dec 30.

PMID:
30597688
14.

The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development.

Krystal AD, Pizzagalli DA, Mathew SJ, Sanacora G, Keefe R, Song A, Calabrese J, Goddard A, Goodman W, Lisanby SH, Smoski M, Weiner R, Iosifescu D, Nurnberger J Jr, Szabo S, Murrough J, Shekhar A, Potter W.

Nat Rev Drug Discov. 2018 Dec 28;18(1):82-84. doi: 10.1038/nrd.2018.222. No abstract available.

PMID:
30591715
15.

ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol.

Mathew SJ, Wilkinson ST, Altinay M, Asghar-Ali A, Chang LC, Collins KA, Dale RM, Hu B, Krishnan K, Kellner CH, Malone DA, Murrough JW, Ostroff RB, Sanacora G, Shao M, Anand A.

Contemp Clin Trials. 2019 Feb;77:19-26. doi: 10.1016/j.cct.2018.12.009. Epub 2018 Dec 17.

PMID:
30572160
16.

DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder.

Pape JC, Carrillo-Roa T, Rothbaum BO, Nemeroff CB, Czamara D, Zannas AS, Iosifescu D, Mathew SJ, Neylan TC, Mayberg HS, Dunlop BW, Binder EB.

Clin Epigenetics. 2018 Nov 3;10(1):136. doi: 10.1186/s13148-018-0569-x.

17.

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI.

Mol Psychiatry. 2018 Oct 3. doi: 10.1038/s41380-018-0256-5. [Epub ahead of print] Erratum in: Mol Psychiatry. 2019 Jan 7;:.

18.

Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression.

Wilkinson ST, Kiselycznyk C, Banasr M, Webler RD, Haile C, Mathew SJ.

J Affect Disord. 2018 Dec 1;241:514-518. doi: 10.1016/j.jad.2018.08.075. Epub 2018 Aug 18.

PMID:
30153634
19.

Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder.

Gould F, Dunlop BW, Rosenthal JB, Iosifescu DV, Mathew SJ, Neylan TC, Rothbaum BO, Nemeroff CB, Harvey PD.

Arch Clin Neuropsychol. 2019 Jun 1;34(4):539-547. doi: 10.1093/arclin/acy064.

20.

Early Life Stress Associated With Increased Striatal N-Acetyl-Aspartate: Cerebrospinal Fluid Corticotropin-Releasing Factor Concentrations, Hippocampal Volume, Body Mass and Behavioral Correlates.

Coplan JD, Lu D, El Sehamy AM, Tang C, Jackowski AP, Abdallah CG, Nemeroff CB, Owens MJ, Mathew SJ, Gorman JM.

Chronic Stress (Thousand Oaks). 2018 Jan-Dec;2. doi: 10.1177/2470547018768450. Epub 2018 Apr 18.

21.

Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder.

Hodgins GE, Blommel JG, Dunlop BW, Iosifescu D, Mathew SJ, Neylan TC, Mayberg HS, Harvey PD.

J Clin Psychopharmacol. 2018 Jun;38(3):200-206. doi: 10.1097/JCP.0000000000000858.

22.

The Neurobiological Mechanisms of Generalized Anxiety Disorder and Chronic Stress.

Patriquin MA, Mathew SJ.

Chronic Stress (Thousand Oaks). 2017 Jan-Dec;1. doi: 10.1177/2470547017703993. Epub 2017 Jun 8.

23.

SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.

Saini M, Verma A, Mathew SJ.

Cell Death Dis. 2018 Feb 14;9(2):237. doi: 10.1038/s41419-018-0261-2.

24.

Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ.

Coplan JD, Webler R, Gopinath S, Abdallah CG, Mathew SJ.

J Affect Disord. 2018 Mar 15;229:1-13. doi: 10.1016/j.jad.2017.12.001. Epub 2017 Dec 12.

PMID:
29288871
25.

Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment.

Abdallah CG, Averill CL, Salas R, Averill LA, Baldwin PR, Krystal JH, Mathew SJ, Mathalon DH.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Oct;2(7):566-574. doi: 10.1016/j.bpsc.2017.04.006.

26.

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.

Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA Jr, Sanacora G.

Am J Psychiatry. 2018 Feb 1;175(2):150-158. doi: 10.1176/appi.ajp.2017.17040472. Epub 2017 Oct 3. Review.

27.

Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder.

Dunlop BW, Binder EB, Iosifescu D, Mathew SJ, Neylan TC, Pape JC, Carrillo-Roa T, Green C, Kinkead B, Grigoriadis D, Rothbaum BO, Nemeroff CB, Mayberg HS.

Biol Psychiatry. 2017 Dec 15;82(12):866-874. doi: 10.1016/j.biopsych.2017.06.024. Epub 2017 Jul 4.

28.

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.

Mathew SJ, Gueorguieva R, Brandt C, Fava M, Sanacora G.

Neuropsychopharmacology. 2017 Dec;42(13):2567-2574. doi: 10.1038/npp.2017.106. Epub 2017 May 29.

29.

Targeting glutamate signalling in depression: progress and prospects.

Murrough JW, Abdallah CG, Mathew SJ.

Nat Rev Drug Discov. 2017 Jul;16(7):472-486. doi: 10.1038/nrd.2017.16. Epub 2017 Mar 17. Review.

PMID:
28303025
30.

The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder.

Abdallah CG, Jackowski A, Salas R, Gupta S, Sato JR, Mao X, Coplan JD, Shungu DC, Mathew SJ.

Neuropsychopharmacology. 2017 Jul;42(8):1739-1746. doi: 10.1038/npp.2017.49. Epub 2017 Mar 8.

31.

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.

Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB; American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments.

JAMA Psychiatry. 2017 Apr 1;74(4):399-405. doi: 10.1001/jamapsychiatry.2017.0080. Review.

PMID:
28249076
32.

Neurometabolic Abnormalities in Treatment-Resistant Depression.

Mathew SJ, Lijffijt M.

Am J Psychiatry. 2017 Jan 1;174(1):3-5. doi: 10.1176/appi.ajp.2016.16101154. No abstract available.

PMID:
28041002
33.

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.

Sanacora G, Johnson MR, Khan A, Atkinson SD, Riesenberg RR, Schronen JP, Burke MA, Zajecka JM, Barra L, Su HL, Posener JA, Bui KH, Quirk MC, Piser TM, Mathew SJ, Pathak S.

Neuropsychopharmacology. 2017 Mar;42(4):844-853. doi: 10.1038/npp.2016.224. Epub 2016 Sep 29.

34.

Heightened early-attentional stimulus orienting and impulsive action in men with antisocial personality disorder.

Lijffijt M, Lane SD, Mathew SJ, Stanford MS, Swann AC.

Eur Arch Psychiatry Clin Neurosci. 2017 Oct;267(7):697-707. doi: 10.1007/s00406-016-0734-1. Epub 2016 Sep 23.

PMID:
27662886
35.

Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders.

Sanacora G, Heimer H, Hartman D, Mathew SJ, Frye M, Nemeroff C, Robinson Beale R.

Neuropsychopharmacology. 2017 May;42(6):1179-1181. doi: 10.1038/npp.2016.193. Epub 2016 Sep 19. No abstract available.

36.

Patterns of anterior versus posterior white matter fractional anistotropy concordance in adult nonhuman primates: Effects of early life stress.

Coplan JD, Kolavennu V, Abdallah CG, Mathew SJ, Perera TD, Pantol G, Carpenter D, Tang C.

J Affect Disord. 2016 Mar 1;192:167-75. doi: 10.1016/j.jad.2015.11.049. Epub 2015 Dec 9.

37.

Impact of childhood emotional abuse on neocortical neurometabolites and complex emotional processing in patients with generalized anxiety disorder.

Raparia E, Coplan JD, Abdallah CG, Hof PR, Mao X, Mathew SJ, Shungu DC.

J Affect Disord. 2016 Jan 15;190:414-423. doi: 10.1016/j.jad.2015.09.019. Epub 2015 Oct 23.

PMID:
26551399
38.

Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches.

Al Jurdi RK, Swann A, Mathew SJ.

Curr Psychiatry Rep. 2015 Oct;17(10):81. doi: 10.1007/s11920-015-0614-9. Review.

PMID:
26307033
39.

The Groucho/Transducin-like enhancer of split protein family in animal development.

Agarwal M, Kumar P, Mathew SJ.

IUBMB Life. 2015 Jul;67(7):472-81. doi: 10.1002/iub.1395. Epub 2015 Jul 14. Review. Erratum in: IUBMB Life. 2019 Nov;71(11):1824.

40.

Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder.

Abdallah CG, Jackowski A, Sato JR, Mao X, Kang G, Cheema R, Coplan JD, Mathew SJ, Shungu DC.

Eur Neuropsychopharmacol. 2015 Aug;25(8):1082-90. doi: 10.1016/j.euroneuro.2015.04.025. Epub 2015 May 5.

41.

Muscle stem cells contribute to myofibres in sedentary adult mice.

Keefe AC, Lawson JA, Flygare SD, Fox ZD, Colasanto MP, Mathew SJ, Yandell M, Kardon G.

Nat Commun. 2015 May 14;6:7087. doi: 10.1038/ncomms8087.

42.

Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies.

Bhagwagar Z, Torbeyns A, Hennicken D, Zheng M, Dunlop BW, Mathew SJ, Khan A, Weisler R, Nelson C, Shelton R, Thase ME, Lane R.

J Clin Psychopharmacol. 2015 Aug;35(4):454-9. doi: 10.1097/JCP.0000000000000335.

PMID:
25961781
43.

Enhanced Olfactory Cortex Connectivity in a Patient With PTSD With Olfactory Hallucinations.

Ridgewell C, Bray A, Curtis K, Velasquez K, Baldwin PR, Fowler JC, Mathew SJ, Salas R.

J Neuropsychiatry Clin Neurosci. 2015;27(2):e170-1. doi: 10.1176/appi.neuropsych.14070156. No abstract available.

PMID:
25923873
44.

A Novel Anxiety and Affective Spectrum Disorder of Mind and Body-The ALPIM (Anxiety-Laxity-Pain-Immune-Mood) Syndrome: A Preliminary Report.

Coplan J, Singh D, Gopinath S, Mathew SJ, Bulbena A.

J Neuropsychiatry Clin Neurosci. 2015;27(2):93-103. doi: 10.1176/appi.neuropsych.14060132.

PMID:
25923849
45.

Does ketamine have anti-suicidal properties? Current status and future directions.

Price RB, Mathew SJ.

CNS Drugs. 2015 Mar;29(3):181-8. doi: 10.1007/s40263-015-0232-4. Review.

46.

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.

Murrough JW, Collins KA, Fields J, DeWilde KE, Phillips ML, Mathew SJ, Wong E, Tang CY, Charney DS, Iosifescu DV.

Transl Psychiatry. 2015 Feb 17;5:e509. doi: 10.1038/tp.2015.10.

47.

The promise of ketamine for treatment-resistant depression: current evidence and future directions.

DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV.

Ann N Y Acad Sci. 2015 May;1345:47-58. doi: 10.1111/nyas.12646. Epub 2015 Feb 3. Review.

48.

Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid in macaques following early life stress and inverse association with hippocampal volume: preliminary implications for serotonin-related function in mood and anxiety disorders.

Coplan JD, Fulton SL, Reiner W, Jackowski A, Panthangi V, Perera TD, Gorman JM, Huang YY, Tang CY, Hof PR, Kaffman A, Dwork AJ, Mathew SJ, Kaufman J, Mann JJ.

Front Behav Neurosci. 2014 Dec 23;8:440. doi: 10.3389/fnbeh.2014.00440. eCollection 2014.

49.

Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.

Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, Foulkes A, Charney DS, Mathew SJ, Iosifescu DV.

Neuropsychopharmacology. 2015 Mar 13;40(5):1084-90. doi: 10.1038/npp.2014.298.

50.

Early life stress and macaque amygdala hypertrophy: preliminary evidence for a role for the serotonin transporter gene.

Coplan JD, Fathy HM, Jackowski AP, Tang CY, Perera TD, Mathew SJ, Martinez J, Abdallah CG, Dwork AJ, Pantol G, Carpenter D, Gorman JM, Nemeroff CB, Owens MJ, Kaffman A, Kaufman J.

Front Behav Neurosci. 2014 Oct 6;8:342. doi: 10.3389/fnbeh.2014.00342. eCollection 2014.

Supplemental Content

Loading ...
Support Center